What is GlycoMimetics Price-to-Operating-Cash-Flow?
As of today (2024-04-28), GlycoMimetics's share price is $1.64.
GlycoMimetics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55. Hence, GlycoMimetics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for GlycoMimetics's Price-to-Operating-Cash-Flow or its related term are showing as below:
GlycoMimetics's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.12.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 13.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 10.60% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 7.40% per year.
During the past 13 years, GlycoMimetics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 63.30% per year. The lowest was -63.40% per year. And the median was 5.40% per year.
GlycoMimetics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for GlycoMimetics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics Price-to-Operating-Cash-Flow Chart
|
GlycoMimetics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
GlycoMimetics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of GlycoMimetics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, GlycoMimetics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoMimetics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoMimetics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where GlycoMimetics's Price-to-Operating-Cash-Flow falls into.
GlycoMimetics Price-to-Operating-Cash-Flow Calculation
GlycoMimetics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 1.64 | / | -0.554 |
| = | |
GlycoMimetics's Share Price of today is $1.64.
GlycoMimetics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
GlycoMimetics (GlycoMimetics) Business Description
Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Executives
| Edwin Rock |
officer: Chief Medical Officer |
9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Brian M. Hahn |
officer: CFO |
C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
| Daniel M Junius |
director |
C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
| Bruce S Johnson |
officer: SVP & Chief Commercial Officer |
9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850 |
| Chinmaya Rath |
officer: SVP and Chief Business Officer |
9708 MEDICAL CENTER DR., ROCKVILLE MD 20850 |
| Invus Public Equities, L.p. |
10 percent owner |
C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
| Invus Public Equities Advisors, Llc |
10 percent owner |
C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
| Artal Group S.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Artal International S.c.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| S.a. Westend |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Administratiekantoor Westend Stichting |
10 percent owner |
CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD |
| Artal International Management S.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Amaury Wittouck |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661 |
| Scott D Sandell |
10 percent owner |
|
| Harout Semerjian |
director, officer: Chief Executive Officer |
300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950 |
GlycoMimetics (GlycoMimetics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLYC has been successfully added to your